SCHEMBL8299287

SCHEMBL8299287

CC1CCc2c(nc(-c3ccccc3O)nc2N2CCN(C)CC2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
ADORA1 P30542 1/20 0.53
ALDH1A1 P00352 5/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMAD3 P84022 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 4/20 0.41
LMNA P02545 1/20 0.41
HRH1 P35367 2/20 0.41
HRH4 Q9H3N8 2/20 0.41
HRH2 P25021 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150326 0.91 MEN1 (0.57) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL8297570 0.91 SMAD3 (0.53) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL8297579 0.91 ALDH1A1 (0.53) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL10150306 0.91 SMAD3 (0.53) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL10150299 0.91 ALDH1A1 (0.53) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL10150291 0.90 SMAD3 (0.52) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL10150296 0.90 SMAD3 (0.52) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL8299276 0.90 SMAD3 (0.52) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL8299280 0.89 ALDH1A1 (0.46) MEN1KMT2AADORA1ALDH1A1MAPT
SCHEMBL10150300 0.88 PIK3CA (0.52) MEN1KMT2AADORA1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
WO-2005014558-A1 CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 MEN1 2441/4885KMT2A 3069/4885ADORA1 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.